Matthew Lang - Feb 9, 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Business Officer
Signature: /s/ Matthew Lang
Stock symbol: LYEL
Transactions as of: Feb 9, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/13/2024, 08:25 PM
Previous filing: Aug 11, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Award	$0	+50K		$0.00	50K	Feb 9, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award	$0	+500K		$0.00	500K	Feb 9, 2024	Common Stock	500K	$1.80	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.